comparemela.com

Latest Breaking News On - Janssenusand janssen scientific affairs - Page 1 : comparemela.com

Johnson & Johnson : New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)

TITUSVILLE, NJ,March 5, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial. | March 5, 2023

United statesNew orleansMarcp bonacaKaitlin meiserLee pasqualoniMarc bonacaNone of the janssen pharmaceutical companiesDivision of cardiovascular medicineAmerican college of cardiologyUniversity of colorado anschutz medical campusJanssen pharmaceuticals incDrug administrationJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnson

Johnson & Johnson : Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

TITUSVILLE, NJ, December 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that. | December 9, 2022

United statesLee pasqualoniCraigi colemanAmerican heart associationJanssen pharmaceuticals incJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonCardiovascular metabolism at janssen scientific affairsUniversity of connecticutAmerican society of hematologyJanssen scientific affairsJanssenusand janssen scientific affairsNational blood clot allianceCenters for diseaseNone of the janssen pharmaceutical companiesSchool of pharmacy

vimarsana © 2020. All Rights Reserved.